Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a study titled ‘SUNRISE-UC’ to evaluate the effectiveness and safety of risankizumab in patients with moderate to severe ulcerative colitis (UC). The study aims to assess changes in disease activity in a real-world setting, highlighting its significance in providing practical insights into treatment outcomes.
Risankizumab, the intervention being tested, is an approved medication for UC. It is designed to reduce inflammation and improve symptoms in patients with this chronic condition.
The study is observational, following a cohort of approximately 200 participants over a 52-week period. Participants will receive risankizumab as prescribed by their physicians, with no additional burdens beyond routine clinical visits.
The study began on January 3, 2025, with primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 18, 2025, indicating ongoing recruitment and progress.
This study update could influence AbbVie’s stock performance positively by reinforcing investor confidence in its UC treatment portfolio. As the pharmaceutical industry remains competitive, successful outcomes could enhance AbbVie’s market position.
The study is currently recruiting, with further details available on the ClinicalTrials portal.